Overall Score

Bargaining Power Of Suppliers

High gross margin (~94.0%) suggests some pricing power over inputs, but the company still depends on specialized pharmaceutical supply chains.

Negative operating margins indicate supplier costs and commercialization expenses remain meaningful despite strong product economics.

Bargaining Power Of Buyers

Revenue concentration risk remains elevated in a specialty pharma model where payers and prescribers can influence uptake.

A current ratio of 3.34 and cash ratio of 0.74 support near-term resilience, but do not materially reduce buyer leverage.

Threat Of New Entrants

Regulatory and clinical development barriers remain significant in GI therapeutics, limiting easy entry.

However, the absence of positive profitability and a price-to-sales ratio near 2.1 leave room for future competition if differentiation weakens.

Threat Of Substitutes

Specialty GI treatments face substitution risk from alternative therapies and physician prescribing shifts.

Strong gross margin and established commercialization help defend against immediate substitution, but not eliminate it.

Industry Rivalry

Negative EBIT margin (-6.2%) and net margin (-12.4%) indicate ongoing competitive pressure and heavy operating spend.

The company’s scale remains modest with market cap under $1.0B, which can intensify rivalry versus larger GI-focused peers.